We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Arthritis that affects some people with the skin condition psoriasis
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Psoriatic arthritis (PsA) is a type of arthritis that affects some people with the skin condition psoriasis. It typically causes affected joints to become swollen, stiff and painful.
PsA is an inflammatory arthritis that develops in around 15% of people with psoriasis, causing swollen and painful joints. For patients who do not respond to standard arthritis drugs, two classes of biologic drugs are available (TNF or IL-17 blockers). A similar proportion of patients respond to both with around 50% achieving a good response. However, we do not know how to predict which patient will respond best to each drug.
Our aim is to test whether we can predict if people with psoriatic arthritis (PsA) will respond to certain biologic drugs using blood tests. We will test if high levels of a type of T cells (activated Th17 cells) or other laboratory tests predict response. We will use statistical tests to estimate how effective these approaches would be for each individual. If successful, this approach could ensure that patients receive their best option first, ensuring their disease is controlled and quality of life improved, while avoiding unnecessary drug use. This is likely to save money for the NHS.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
2023 Protocol article in https://pubmed.ncbi.nlm.nih.gov/37770264/ (added 29/09/2023)
You can take part if:
Current inclusion criteria as of 15/08/2022:
1. Participant is willing and able to give informed consent for participation in the study
2. Male or female, age 18 years or over
3. Diagnosis of PsA confirmed by the CASPAR criteria
4. Is planned to have biologic therapy for psoriatic arthritis using NICE/SMC criteria (failure of ≥2 csDMARDs and ≥3 tender and ≥3 swollen join
You may not be able to take part if:
1. Contraindications to either TNF inhibitor or secukinumab:1.1. History of previous demyelinating disease including multiple sclerosis1.2. Heart failure (NYHA class 3 or 4)1.3. Serious infections: active tuberculosis (TB), chronic viral infections (including hepatitis B, C and HIV), recent serious bacterial infections1.4. Latent TB unless they have received appropriate anti-tuberculous treatment as per local guidelines1.5. Active symptomatic inflammatory bowel disease1.6. History of cancer in the last 5 years, other than non-melanoma skin cell cancers cured by local resection or carcinoma in situ1.7. Hypersensitivity to active ingredient or excipients2. Current or previous treatment with biologic DMARDs or targeted synthetic DMARDs3. Use of investigational therapies within 1 month or 5 half-lives (whichever is longer) of baseline4. Women who are pregnant, lactating or planning pregnancy during the following 12 months
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Laura
Coates
+44 (0)1865 737838
laura.coates@ndorms.ox.ac.uk
The study is sponsored by University of Oxford and funded by NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC); Grant Codes: NIHR129023; National Institute for Health Research (NIHR) (UK).
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 48066
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
